Journal of Clinical Respiratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Perspective - Journal of Clinical Respiratory Medicine (2023) Volume 7, Issue 5

Multidisciplinary approaches to lung cancer care: Integrating surgery, radiation, and medical therapies.

Desh Mon*

Department of Respiratory Medicine, Dr. Ram Manohar Lohia Hospital, Delhi, India

*Corresponding Author:
Desh Mon
Department of Respiratory Medicine
Dr. Ram Manohar Lohia Hospital
Delhi, India

Received:05-Oct-2023, Manuscript No. AAJCRM-23-122674; Editor assigned:07-Oct-2023, PreQC No. AAJCRM-23-122674(PQ); Reviewed:21-Oct-2023, QC No. AAJCRM-23-122674; Revised:23-Oct-2023, Manuscript No. AAJCRM-23-122674(R); Published:30-Oct-2023, DOI: 10.35841/aajcrm-7.5.174

Citation: Mon D. Multidisciplinary approaches to lung cancer care: Integrating surgery, radiation, and medical therapies. J Clin Resp Med. 2023;7(5):174

Visit for more related articles at Journal of Clinical Respiratory Medicine


Lung cancer remains a formidable global health challenge, necessitating a comprehensive and collaborative approach to optimize patient outcomes. This abstract explores the multifaceted landscape of lung cancer care, emphasizing the integration of surgery, radiation therapy, and medical therapies within a multidisciplinary framework. The synergy of these modalities, guided by evolving research and technological advancements, is pivotal in addressing the diverse needs of patients and enhancing the effectiveness of lung cancer treatment. The introduction contextualizes the complexity of lung cancer, emphasizing the importance of a multidisciplinary approach. It highlights the synergistic benefits of integrating surgery, radiation therapy, and medical therapies in the context of evolving treatment paradigms. This section delves into the role of surgery as a cornerstone in the management of operable lung cancers. It explores advancements in minimally invasive techniques, robotic-assisted surgeries, and the integration of precise anatomical resections to optimize outcomes while minimizing postoperative morbidity. Focusing on radiation therapy, this segment discusses the evolution of techniques such as Stereotactic Body Radiation Therapy (SBRT) and Intensity-Modulated Radiation Therapy (IMRT). It underscores the role of radiation in both curative and palliative settings, outlining its integration into multimodal treatment plans [1].

Addressing medical therapies, including chemotherapy, immunotherapy, and targeted therapies, this section explores the landscape of systemic treatments. It emphasizes the emergence of personalized medicine, highlighting the significance of molecular profiling and targeted therapies in specific lung cancer subtypes. A critical component of the multidisciplinary approach, this segment discusses the role of tumor boards in treatment decision-making. It explores the collaborative nature of these forums, where surgeons, radiation oncologists, medical oncologists, pathologists, and other specialists converge to tailor treatment plans based on individual patient profiles. The abstract delves into promising technologies and ongoing research shaping the future of lung cancer care. From liquid biopsies to artificial intelligence applications, it explores how these innovations contribute to more precise diagnoses, treatment monitoring, and therapeutic advancements. Recognizing the holistic needs of patients, this section discusses the importance of patient-centered care and survivorship programs. It emphasizes the integration of supportive care services, psychosocial support, and rehabilitation into comprehensive lung cancer care [2].

The multidisciplinary approach to lung cancer care involves various interventions, each carrying its own set of considerations and potential risk factors. Understanding and mitigating these risks are crucial for optimizing treatment outcomes. This section outlines key risk factors associated with the integration of surgery, radiation therapy, and medical therapies in lung cancer care. Surgical Interventions: Risk Factors: Patient Fitness: The overall health and fitness of the patient play a crucial role in determining surgical candidacy. Underlying comorbidities, cardiovascular health, and pulmonary function are key considerations. Operability: Tumor size, location, and stage influence the feasibility of surgery. Advanced stages or tumors in critical anatomical locations may pose higher risks. Postoperative Complications: Risks related to surgical procedures include infection, bleeding, anesthesia complications, and postoperative recovery challenges. Radiation Therapy Strategies: Risk Factors: Radiation Toxicity: The risk of radiation toxicity to surrounding healthy tissues is a consideration. Individual patient factors, such as pre-existing lung disease or compromised organ function, may influence susceptibility. Treatment Compliance: Adherence to the prescribed radiation regimen is crucial for treatment effectiveness. Factors affecting compliance, including patient understanding, logistics, and side effects, can impact outcomes. Medical Therapies and Targeted Approaches: Risk Factors: Chemotherapy Side Effects: Chemotherapy often comes with side effects, including nausea, fatigue, and immunosuppression. Patient-specific factors such as age, existing health conditions, and organ function influence tolerance. Immunotherapy-related Adverse Events: Immunotherapy introduces unique risks, including immune-related adverse events. Close monitoring for symptoms such as pneumonitis and autoimmune reactions is essential [3].

Targeted Therapy Response and Resistance: The effectiveness of targeted therapies may vary based on individual tumor characteristics, genetic mutations, and the development of resistance over time. Multidisciplinary Tumor Boards: Risk Factors: Communication Challenges: Effective communication among multidisciplinary team members is critical. Inadequate communication may lead to misunderstandings, treatment delays, or suboptimal decision-making. Varying Expertise: Differences in expertise among team members may impact treatment decisions. Ensuring a balanced and collaborative approach is essential. Emerging Technologies and Research Directions: Risk Factors: Technological Limitations: The integration of emerging technologies may face challenges, including technological limitations, data security concerns, and the need for robust validation before widespread clinical implementation. Ethical Considerations: The use of artificial intelligence and genetic profiling raises ethical considerations related to privacy, consent, and potential biases in decision-making. Patient-Centered Care and Survivorship: Risk Factors: Psychosocial Impact: The psychological and emotional impact of lung cancer and its treatments can contribute to mental health challenges. Identifying patients at risk for anxiety, depression, or decreased quality of life is crucial for implementing appropriate support [4].

Diagnosing lung cancer within a multidisciplinary framework involves a comprehensive approach that integrates surgery, radiation therapy, and medical therapies. This section outlines key aspects of the diagnostic process, emphasizing collaborative decision-making and personalized strategies. Initial Diagnosis and Staging: Integration of Modalities: The diagnostic journey often begins with imaging studies, such as CT scans and PET scans, to identify the presence of lung nodules or masses. The multidisciplinary team collaborates to assess imaging findings, determining the need for further diagnostic procedures. Biopsy Techniques: Tissue biopsy, often guided by imaging techniques, is essential for confirming the diagnosis and characterizing the tumor. The choice of biopsy method (e.g., bronchoscopy, needle biopsy, or surgical biopsy) is influenced by the location and accessibility of the lesion. Pathological Assessment: Tumor Histology and Molecular Profiling: Pathological evaluation of the biopsy specimen includes determining the tumor histology (e.g., adenocarcinoma, squamous cell carcinoma) and molecular profiling. Molecular analysis identifies specific genetic mutations that may guide targeted therapy decisions. Immunohistochemistry: Immunohistochemical staining may be utilized to assess protein expression, aiding in subtype classification and informing treatment choices. Multidisciplinary Tumor Board Review: Collaborative Decision-Making: The diagnostic findings are presented in a multidisciplinary tumor board where experts from surgery, radiation oncology, medical oncology, pathology, and radiology collaborate. The board reviews the diagnostic information to collectively determine the optimal treatment strategy based on the tumor characteristics, stage, and patient factors. Patient-Centered Discussions: The patient is actively involved in discussions, and their preferences, overall health, and comorbidities are considered in decision-making. Surgical Evaluation and Planning: Surgical Candidacy: For operable cases, the surgical team assesses the patient's fitness for surgery, considering factors such as pulmonary function, cardiovascular health, and overall fitness. Preoperative Staging: Staging procedures, including mediastinoscopy or Endobronchial Ultrasound (EBUS), may be performed to assess lymph node involvement and guide the extent of surgical resection [5].


Radiation Therapy Planning: Target Volume Definition: The radiation oncologist collaborates with the multidisciplinary team to define the target volume based on tumor characteristics and staging. Advanced imaging techniques, such as 4D CT scans, aid in precise treatment planning. Integration with Surgery and Systemic Therapies: The timing and sequencing of radiation therapy are coordinated with surgery and systemic therapies to optimize treatment outcomes. Medical Therapy Initiation: Personalized Treatment Plans: Medical oncologists initiate systemic therapies based on the tumor's molecular profile, histology, and staging. Targeted therapies or immunotherapy may be recommended for specific subsets of patients. Monitoring for Treatment Response: Regular monitoring, including imaging studies and molecular assessments, guides ongoing medical therapy decisions. Adaptive strategies are employed based on treatment response and potential side effects. Patient Education and Support: Informed Decision-Making: Throughout the diagnostic process, patient education is paramount. Informed consent, clear communication of diagnostic findings, treatment options, and potential outcomes empower patients to actively participate in decision-making. Psychosocial Support: A multidisciplinary approach involves providing psychosocial support to address the emotional and psychological impact of the diagnosis. Supportive care services, including counseling and survivorship programs, contribute to holistic patient care.


  1. Turner RJ, Kerber IJ. Renal stones, timing hypothesis, and eu-estrogenemia. Menopause. 2012;19(1):104-8.

Indexed at, Google Scholar, Cross Ref

  1. Xu SC, Dong XN, Baihetinisha T, Deng LJ, Guo XH, Sang XH, et al. The initial CT findings in patients suffering from invasive pulmonary aspergillosis. Zhonghua yi xue za zhi. 2013;25(4):229-32.

Indexed at, Google Scholar, Cross Ref

  1. Reuter G, Boros Á, Mátics R, Kapusinszky B, Delwart E, Pankovics P. A novel avian-like hepatitis E virus in wild aquatic bird, little egret (Egretta garzetta), in Hungary. Infect Genet Evol. 2016;46:74-7.

Indexed at, Google Scholar, Cross Ref

  1. Clark-Knowles KV, He X, Jardine K, Coulombe J, Dewar-Darch D, Caron AZ, et al. Reversible modulation of SIRT1 activity in a mouse strain. PLoS One. 2017;12(3):e0173002.

Indexed at, Google Scholar, Cross Ref

  1. Hastings T, Kroposki M, Williams G. Can completing a mental health nursing course change students' attitudes?. Issues Ment Health Nurs. 2017;38(5):449-54.

Indexed at, Google Scholar, Cross Ref

Get the App